RSV Prophylaxis Guidelines for High-Risk Infants
Eligibility Criteria
- The American Academy of Pediatrics recommends palivizumab prophylaxis for infants born before 29 weeks, 0 days' gestation 1, 2
- Infants with chronic lung disease who received medical therapy within 6 months before the start of the RSV season are eligible for palivizumab prophylaxis 3, 4
- Children with pulmonary abnormality or neuromuscular disease that impairs the ability to clear secretions from the upper airways are eligible for palivizumab prophylaxis 1, 2
- Infants with congenital abnormalities of the airway or neuromuscular conditions that compromise handling of respiratory tract secretions are eligible for palivizumab prophylaxis 3, 5
Dosing Schedule
- The recommended dose of palivizumab is 15 mg/kg body weight by intramuscular injection, administered monthly throughout the RSV season 1, 6
- The maximum number of doses recommended is 5 monthly doses 1, 6
- The timing of the doses depends on the start date, with the goal of continuing for 5 monthly doses 1, 6
Special Considerations
- Children who undergo cardiac bypass or extracorporeal membrane oxygenation should receive an additional dose of palivizumab after the procedure 2, 7
- Infants in a neonatal unit who qualify for prophylaxis may receive the first dose 48 to 72 hours before discharge to home or promptly after discharge 1, 6
- If a child receiving monthly palivizumab prophylaxis experiences a breakthrough RSV hospitalization, monthly prophylaxis should be discontinued due to the extremely low likelihood of a second RSV hospitalization in the same season 8, 2
Efficacy and Limitations
- Palivizumab prophylaxis is not effective for treatment of established RSV disease 1, 6
- Prophylaxis is not recommended for primary asthma prevention or to reduce subsequent episodes of wheezing 1, 2
Additional Preventive Measures
- The American Academy of Pediatrics recommends keeping high-risk infants away from crowds and situations where exposure to infected people cannot be controlled 3, 4
- Restricting participation in group child care during RSV season when feasible is recommended 3, 5
- Practicing careful hand hygiene is recommended 3, 4
- Ensuring all eligible infants and their contacts receive influenza vaccine and other age-appropriate immunizations is recommended 3, 5
- Eliminating exposure to tobacco smoke is recommended 3, 5
Common Pitfalls
- Failure to administer an additional dose after cardiac bypass surgery can result in suboptimal protection due to a 58% decrease in palivizumab serum concentration following this procedure 2, 7
RSV Prevention in High-Risk Infants
Eligibility Criteria and Prophylaxis
- Infants 29-31 weeks gestation should receive palivizumab prophylaxis if younger than 6 months at the start of RSV season, with a maximum of 5 monthly doses, as recommended by the American Academy of Pediatrics 9
- Infants 32-34 weeks gestation should only receive prophylaxis if younger than 3 months at start of RSV season and have at least one risk factor, such as attending child care or having a sibling younger than 5 years, with a maximum of 3 doses, as recommended by the American Academy of Pediatrics 9
High-Risk Groups Requiring Prophylaxis
- Infants younger than 24 months with hemodynamically significant congenital heart disease, including acyanotic heart disease receiving medication for congestive heart failure, moderate-to-severe pulmonary hypertension, or cyanotic heart disease, should receive palivizumab prophylaxis, as recommended by the American Academy of Pediatrics 10
Dosing Schedule and Administration
- The first dose of palivizumab should be given 48-72 hours before hospital discharge or promptly after discharge if the infant qualifies during RSV season, as recommended by the American Academy of Pediatrics 10
- After cardiac bypass surgery, an additional dose of palivizumab should be given as soon as medically stable, even if less than 1 month from the previous dose, due to a 58% decrease in palivizumab levels, as recommended by the American Academy of Pediatrics 10
Essential Non-Pharmacologic Prevention Measures
- Complete elimination of tobacco smoke exposure is essential for all high-risk infants, regardless of palivizumab use, as recommended by the American Academy of Pediatrics 10
- Avoiding crowds and situations where exposure to infected people cannot be controlled is crucial for all high-risk infants, regardless of palivizumab use, as recommended by the American Academy of Pediatrics 9
- Restricting group child care participation during RSV season when feasible is recommended for all high-risk infants, regardless of palivizumab use, as recommended by the American Academy of Pediatrics 10
- Strict hand hygiene by all caregivers and family members is essential for all high-risk infants, regardless of palivizumab use, as recommended by the American Academy of Pediatrics 10
Palivizumab Prophylaxis Eligibility and Expected Clinical Benefit
Eligibility Criteria
- Infants born before 29 weeks 0 days gestation and who are younger than 12 months at the start of the RSV season are eligible to receive palivizumab prophylaxis according to the American Academy of Pediatrics guidelines. 11
Expected Clinical Benefit
- Palivizumab reduces the risk of RSV‑related hospitalization in high‑risk infants but does not affect mortality and has minimal impact on subsequent wheezing; its benefit is therefore limited to preventing hospital admission. (American Academy of Pediatrics) 11
Management Implications
- Providing only reassurance to an infant who meets the above eligibility criteria is inadequate, as it forgoes a proven opportunity to lower the risk of severe RSV disease. (American Academy of Pediatrics) 11